InvestorsHub Logo
Followers 7
Posts 528
Boards Moderated 0
Alias Born 02/13/2020

Re: meluto post# 25318

Sunday, 12/13/2020 5:20:51 PM

Sunday, December 13, 2020 5:20:51 PM

Post# of 27112
Agreed that $ABMC growth can only come by increasing and adding new products.

Just letting you know that the oral fluid drug testing platform has been available throughout 2020. The decline in the need for drug testing put the "introduction" and the "sales" of this product on the back burner. As companies have settled into a new work flow during the pandemic, drug test sales have been slowly increasing, but are not near pre-pandemic levels.

Most importantly the new oral drug platform was the test the company was relying on to increase sales from the previous years of poor performance. So getting the word out and introducing it to the world is definitely helpful.


As far as announcing new clients or contracts for in house manufacturing, we will never hear about them. It was only gleaned through an email that the contracts can take months to a year to come to fruition. So even if the deals negotiations began in 2019, they are not old news. It is possible manufacturing has just recently commenced.

Of course, new manufacturing contracts are always welcomed. These type of contracts are difficult to gain due to very, very, heavy overseas competition, so if a contract is signed, it should be valuable to bottom line sales.